Economic Burden of Contraception Management in Spain

Inmaculada Parra Ribes1*, Juan José Rascón Poza2, Ezequiel Pérez Campos3, Ignacio Bugella Yudice4, Maria Jesús Rodríguez Domingo5

1Unidad de Salud Sexual y Reproductiva de Sueca, Valencia, Spain; 2Centro de Salud Mediterráneo, Almería, Spain; 3Hospital de Requena, Valencia, Spain; 4Centro Planificación de Getafe, Madrid, Spain; 5Centro ASSIR Viladecans, Barcelona, Spain

*Corresponding author iparrar@comv.es

Abstract

Background: A wide variety of contraceptive methods are available, some of them reimbursed by the Spanish National Health System (SNHS). However, the number of unintended pregnancies (UP) is still significant, leading to a high economic burden, mainly derived from non-adherence to and the incorrect use of contraceptive methods.

Objectives: This study aims to estimate the economic burden associated with reversible contraception management in Spain, from the perspectives of both the SNHS and women, over a 5-year period.

Methods: A survey was performed to identify contraception management in Spain based on the experience of a panel of six expert gynecologists. An economic model was conducted to quantify the current burden of contraception according to healthcare resources use over 5 years. The costs included in the analysis were diagnostic tests, initial and follow-up consultations, methods acquisition costs, and UP derived from therapy failure.

Results: Reversible contraception costs in Spain amount to €12.5 billion over a 5–year period. Condoms and combined oral contraceptives (COC) account for 86.8% of the total cost and the other methods only 13.2%. There are differences in contraceptive use according to women’s age. Short-acting reversible contraceptives (SARC) such as COC, condom and vaginal ring, are most commonly used by younger women. However, SARC are correlated with the highest failure rate, resulting in over €7.2 billion cost, explained by the high number of UP. Long-acting reversible contraceptives (LARC), such as the levonorgestrel-releasing intrauterine system (LNG-IUS20), implant and copper intrauterine devices (IUD), are selected by women over 35 years of age due to user-independent compliance. SARC methods result in a higher cost per woman over 5 years: vaginal ring €2427.8, patch €2402.6, condom €2060.1 and COC €1895.1; while LARC methods are the most economic option per women: LNG-IUS20 €630.4, copper IUD €658.2, LNG-IUS12 €703.8, intramuscular injectable €907.8 and implant €940.5.

Conclusions: LARC methods result in lower costs compared with SARC options from the perspectives of the SNHS and women, explained by user-independent compliance, preventing a significant number of UP and its elevated economic burden. An increased LARC methods use could avoid UP events, leading to significant cost-savings for the SNHS.

Keywords: economic burden, intrauterine system, long-acting reversible contraceptives, reversible contraception, short-acting reversible contraceptives, unintended pregnancy
Background

A wide variety of contraceptive products are available in Spain and some, such as oral contraceptive (OC) pills, injections, and implants, are reimbursed by the Spanish National Health System (SNHS). However, the number of unintended pregnancies (UPs) is still considerable, leading to high potentially avoidable expenditures by the SNHS with greater use of user-independent compliance methods, such as long-acting reversible contraceptives (LARC).1

From 1997 to 2007, Spain experienced a 30.0% increase in the use of contraception.2 In the Spanish contraception survey of 2016, 71.1% of women of childbearing age, between 14 and 49 years, responded that they used contraceptive methods, while 4.1% did not know/did not answer, and 24.7% of women did not use any contraception.3 Among the latter, 8.3% did not have sexual intercourse, but the remaining 16.4% of women may be at risk of UP due to the lack of contraception use, or even the use of ineffective methods (1.0%), such as coitus interruptus or natural methods.3 Among all contraceptive methods used in Spain, reversible methods are employed by 87.3% of women, that is to say, by up to 6.8 million women.4 Reversible methods include short-acting reversible contraceptives (SARC) (combined oral contraceptives [COC], gestagen-only oral contraceptives [OCs], transdermal patch, vaginal ring, male condom) and LARC (subdermal implant [Implanon NXT®, progestagen-only implant], intramuscular injectable [Depo-Provera®, Medroxyprogesterone Acetate Injectable Suspension], LNG-IUS and copper intrauterine device [IUD]). The most common methods are male condom and COC, used by 45.7% and 34.9% of women, respectively.3

Despite an increase in the use of contraception in recent years, the number of elective abortions has risen, mainly attributed to the lack of compliance with or incorrect use of methods requiring frequent dosing.2 A recent study among Spanish women who had had an induced abortion showed that 64.0% of them were using contraceptive methods, mainly condom (40.0%) and COC (14.0%).5 Failure of the method due to incorrect use was reported by 77.0% of the women using condoms and by 84.0% of those using hormonal contraception.5

A better and deeper understanding of the country's real situation concerning contraception is required to define and implement appropriate sexual health and contraception policies.

Currently, there are no data on the economic burden of contraception management in Spain for the National Health System. This study is the first to describe the current situation of reversible contraception in Spain and estimate its economic burden from the perspective of both users and the SNHS over a 5–year period.

Methods

In 2015, an ad-hoc questionnaire was designed to ascertain the current utilization of healthcare resources associated with reversible contraception management from the perspective of the SNHS. The questionnaire was structured into five main sections: current use of contraceptive methods in Spain, method withdrawal, medical consultations and diagnostic tests, methods of preference according to women’s age, and prescription patterns/contraception recommendations. Separate estimates were performed in 5-year age groups in order to explore age-specific trends. The questionnaire was answered by a panel of six gynecologists who are experts on contraception.

An economic model was built to estimate the total cost of reversible contraception management in Spain over 5 years based on the inputs provided by the experts. The model represents a 5-year period of use, which allows comparison between different reversible contraception methods with different efficacy duration, ie, SARC and LARC. The population included in the analysis was women of childbearing
age, between 14 and 49 years, managed by the SNHS.

The model includes the most representative healthcare costs associated with the current contraceptive care pathway in Spain: 1) cost of the first visits to the gynecologist to initiate contraceptive therapy; 2) cost per patient and contraception method of diagnostic tests not included in routine consultation; 3) cost per patient and contraception method of the number of follow-up consultations during the 5-year period; 4) contraception acquisition cost during a period of 5 years, either reimbursed by the SNHS or paid by the user, and 5) cost of therapy failure resulting in a UP over 5 years. Costs are expressed in euro (€) 2017. Other costs, such as adverse events related with each contraceptive option (i.e. bleeding irregularities, uterine perforation, pelvic infection or ovarian cysts) were not included in the economic analysis.

The use of reversible contraception was obtained from a survey conducted by the Spanish Society of Contraception (SEC). However, the LNG-IUS12 contraceptive method was not included in this survey since it was not available on the market then. Thus, LNG-IUS12 utilization was provided by the experts based on their experience in the routine clinical practice.

Cost of Contraceptive Therapy Initiation

Contraceptive therapy initiation consists of the first consultation with the gynecologist and diagnostic tests (ultrasound and blood tests), frequently carried out prior to initiating therapy. Unitary costs were calculated according to the average price of the catalogues of public prices of healthcare services of the main Spanish Autonomous Communities (Andalusia, Catalonia, and Madrid), weighted by population, and updated to 2017, based on the Consumer Price Index. The unit cost of the first gynecologist consultation in Spain is €79.1, while the unit cost for diagnostic tests is €23.5 for ultrasounds and €29.9 for blood tests. For the diagnostic tests, costs were weighted by frequency of use. Total contraceptive therapy initiation cost per method was calculated considering the number of women using each method and the annual frequency of diagnostics and initial gynecologist consultations (Table 1, Table 2).

Table 1. Total Cost of the First Consultation with a Gynecologist to Initiate Contraceptive Therapy

| Contraceptive method | Number of women | % of users by method | Average cost per woman of the initial visit (€)* | Total cost associated with initial visits (€ MM) |
|----------------------|-----------------|----------------------|-----------------------------------------------|-----------------------------------------------|
| COC                  | 2 362 775       | 34.9                 | 79.1                                          | 186.9                                         |
| Gestagen-only OCs    | 21 777          | 0.3                  | 79.1                                          | 1.7                                           |
| Vaginal ring         | 370 204         | 5.5                  | 79.1                                          | 29.3                                          |
| Patch                | 54 442          | 0.8                  | 79.1                                          | 4.3                                           |
| Implant              | 87 107          | 1.3                  | 79.1                                          | 6.9                                           |
| Injection            | 21 777          | 0.3                  | 79.1                                          | 1.7                                           |
| LNG-IUS12            | 28 038          | 0.4                  | 79.1                                          | 2.2                                           |
| LNG-IUS20            | 351 694         | 5.2                  | 79.1                                          | 27.8                                          |
| Copper IUD           | 371 565         | 5.5                  | 79.1                                          | 29.4                                          |
| Male condom          | 3 092 295       | 45.7                 | 79.1                                          | 244.6                                         |
| **Total**            | **6 761 674**   | **53.4**             | **534.8**                                     |                                               |

€ MM: € million. *Unit costs were calculated according to the average price of the catalogues of public prices of healthcare services of the main Spanish Autonomous Communities (Andalusia, Catalonia, and Madrid) weighted by population and updated to the year 2017, based on the Consumer Price Index.
Table 2. Total Cost of Diagnostic Tests to Initiate Contraceptive Therapy

| Contraceptive method | Number of women | Ultrasound | Blood test | Average cost per woman (€) | Total cost of diagnostic tests (€ MM) |
|----------------------|----------------|------------|------------|---------------------------|--------------------------------------|
|                      |                | Frequency (%) | Cost (€ MM)* | Frequency (%) | Cost (€ MM)* |               |                          |
| COC                  | 2 362 775      | 70          | 38.9       | 30            | 21.2        | 25.4         | 60.1               |
| Gestagen-only OCs    | 21 777         | 70          | 0.4        | 30            | 0.2         | 25.4         | 0.6                |
| Vaginal ring         | 370 204        | 70          | 6.1        | 30            | 3.3         | 25.4         | 9.4                |
| Patch                | 54 442         | 70          | 0.9        | 30            | 0.5         | 25.4         | 1.4                |
| Implant              | 87 107         | 70          | 1.4        | 30            | 0.8         | 25.4         | 2.2                |
| Injection            | 21 777         | 85          | 0.4        | 30            | 0.2         | 29.0         | 0.6                |
| LNG-IUS12            | 28 038         | 85          | 0.6        | 30            | 0.3         | 29.0         | 0.8                |
| LNG-IUS20            | 351 694        | 85          | 7.0        | 30            | 3.2         | 29.0         | 10.2               |
| Copper IUD           | 371 565        | 85          | 7.4        | 30            | 3.3         | 29.0         | 10.8               |
| Male condom          | 3 092 295      | 0           | 0.0        | 0             | 0.0         | 0.0          | 0.0                |
| Total                | 6 761 674      | 63.1        | 32.9       |               |             | 96.0         |                   |

€ MM: € million.
*Unit costs were calculated according to the average price of the catalogues of public prices of healthcare services of the main Spanish Autonomous Communities (Andalusia, Catalonia and Madrid) weighted by population and updated to the year 2017, based on the Consumer Price Index.9

Cost of Follow-up Consultations

The number of follow-up consultations to the gynecologist varies according to the contraceptive method chosen. Total follow-up costs were estimated based on the number of women using each method, the average number of subsequent consultations per year according to the data provided by the experts, and the unit cost of the follow-up visit, for a 5-year period. The unit cost of a follow-up visit is €52.4, calculated as for the initial visit6-8 (Table 3). The total cost associated to medical management comprises the initial visit, the follow-up consultations and diagnostic tests (Table 4).

Table 3. Total Cost of Follow-up Consultations

| Contraceptive method | Number of women | Average volume of visits in the first and second year (excluding the initial consultation) | Average volume of visits per year | Average cost of follow-up visits per woman in 5 years (€) | Mean costs for 5-year follow-up visits (€ MM) |
|----------------------|----------------|------------------------------------------------------------------|----------------------------------|--------------------------------------------------------|---------------------------------------------|
| COC                  | 2 362 775      | 2.0                                                               | 1.0                              | 255.4                                                  | 603.3                                       |
| Gestagen-only OCs    | 21 777         | 2.7                                                               | 1.3                              | 347.0                                                  | 7.6                                         |
| Vaginal ring         | 370 204        | 1.7                                                               | 0.9                              | 222.6                                                  | 82.4                                        |
| Patch                | 54 442         | 1.8                                                               | 0.9                              | 238.3                                                  | 13.0                                        |
| Implant              | 87 107         | 4.3                                                               | 2.1                              | 556.5                                                  | 48.5                                        |
| Injection            | 21 777         | 1.7                                                               | 0.8                              | 220.0                                                  | 4.8                                         |
| LNG-IUS12            | 28 038         | 2.1                                                               | 1.0                              | 271.1                                                  | 7.6                                         |
| LNG-IUS20            | 351 694        | 3.1                                                               | 1.6                              | 408.6                                                  | 143.7                                       |
| Copper IUD           | 371 565        | 3.4                                                               | 1.7                              | 445.2                                                  | 165.4                                       |
| Male condom          | 3 092 295      | 1.0                                                               | 0.5                              | 124.4                                                  | 384.7                                       |
| Total                | 6 761 674      | 63.1                                                              | 32.9                              |                                                        | 1461.0                                      |

€ MM: € million
Table 4. Total Cost of Associated Medical Management (initial and follow-up consultations and diagnostic tests)

| Contraceptive method | Number of women | Initial visit cost (€ MM) | Mean costs for 5-year follow-up visits (€ MM) | Total cost of diagnostic tests (€ MM) | Total 5-year cost of medical care (visits and diagnostic tests) (€ MM) |
|----------------------|----------------|---------------------------|---------------------------------------------|-------------------------------------|---------------------------------------------------------------------|
| COC                  | 2 362 775      | 186.9                     | 603.3                                       | 60.1                                | 850.3                                                               |
| Gestagen-only OCs    | 21 777         | 1.7                       | 7.6                                         | 0.6                                 | 9.8                                                                 |
| Vaginal ring         | 370 204        | 29.3                      | 82.4                                        | 9.4                                 | 121.1                                                               |
| Patch                | 54 442         | 4.3                       | 13.0                                        | 1.4                                 | 18.7                                                                |
| Implant              | 87 107         | 6.9                       | 48.5                                        | 2.2                                 | 57.6                                                                |
| Injection            | 21 777         | 1.7                       | 4.8                                         | 0.6                                 | 7.1                                                                 |
| LNG-IUS12            | 28 038         | 2.2                       | 7.6                                         | 0.8                                 | 10.6                                                                |
| LNG-IUS20            | 351 694        | 27.8                      | 143.7                                       | 10.2                                | 181.7                                                               |
| Copper IUD           | 371 565        | 29.4                      | 165.4                                       | 10.8                                | 205.6                                                               |
| Male condom          | 3 092 295      | 24.4                      | 384.7                                       | 0.0                                 | 629.3                                                               |
| Total                | 6 761 674      | 534.8                     | 1461.0                                      | 96.0                                | 2091.8                                                              |

€ MM: € million

Cost of Contraceptive Method Acquisition

The cost of the acquisition of each contraceptive method (retail price) was obtained from the records of the SEC³ and the database of the General Council of Official Colleges of Pharmacists.¹⁰ A price reduction was applied in those methods currently reimbursed by the SNHS according to Royal Decree 8/2010.¹¹ The cost associated with each reversible contraceptive method during a period of 5 years was estimated based on the number of users of each method, the frequency of use and the method acquisition price (Table 5).

Table 5. Total Cost of Contraceptive Method Acquisition for a 5-year Period

| Contraceptive method | Number of women | Acquisition cost (Retail Price, incl. VAT) (€)* | Cost for the NHS (Retail Price, incl. VAT) (€)* | Frequency | 5-year acquisition cost (€ MM)^ |
|----------------------|----------------|-----------------------------------------------|-----------------------------------------------|-----------|---------------------------------|
| COC                  | 2 362 775      | 11.2                                          | NA (not reimbursed)                           | Monthly   | 1723.2                          |
| Gestagen-only OCs    | 21 777         | 3.4                                           | NA (not reimbursed)                           | Monthly   | 4.8                             |
| Vaginal ring         | 370 204        | 19.9                                          | NA (not reimbursed)                           | Monthly   | 479.3                           |
| Patch                | 54 442         | 19.3                                          | NA (not reimbursed)                           | Monthly   | 68.3                            |
| Implant              | 87 107         | 137.5                                         | 82.5                                         | 3 years   | 24.0                            |
| Injection            | 21 777         | 2.1                                           | 1.9                                          | 3 months  | 0.9                             |
| LNG-IUS12            | 28 038         | 153.4                                         | NA (not reimbursed)                           | 3 years   | 8.6                             |
| LNG-IUS20            | 351 694        | 95.9”                                         | 95.9                                         | 5 years   | 33.7                            |
| Copper IUD           | 371 565        | 33.3                                          | NA (not reimbursed)                           | 5 years   | 12.4                            |
| Male condom          | 3 092 295      | 0.6                                           | NA (not reimbursed)                           | 83/year   | 757.1                           |
| Total                | 6 761 674      | 3112.3                                        |                                              |           |                                 |

€ MM: € million “ Selling price * Obtained from the SEC survey³ and Bot Plus¹⁰
^ Cost associated with the acquisition of each contraceptive method over a period of 5 years
Contraceptive Therapy Failure/Unintended Pregnancy

The cost of UP was included in the economic burden analysis, considering a time period of 5 years. Each contraceptive method is associated with a percentage of UP (Table 6) attributable to an imperfect method of use (treatment failure rate) in routine practice.\(^1\),\(^12\) This frequency of UP was used to estimate the number of failures per method in a period of 5 years. Each failure leads to a UP, with four possible outcomes: live birth, induced abortion, fetal loss or ectopic pregnancy. The annual number of these events was obtained from the Spanish Ministry of Health, Social Services and Equality (MHSSE)\(^4\) and the Spanish National Statistics Institute\(^13\) consistent with the methodology used in a previous recent publication.\(^1\) The frequency of live births was 50.1%, induced abortion 43.3%, ectopic pregnancy 6.5%, and fetal loss 0.2%.\(^4\),\(^13\) The cost per UP outcome was obtained from the Diagnosis Related Group codes published by the MHSSE.\(^13\) The unit cost associated to each of UP outcome is €2027.9 (live birth), €1487.3 (induced abortion), €1487.3 (fetal loss) and €1991.3 (ectopic pregnancy).\(^14\)

Finally, the cost of UP was the weighted average cost of the four possible UP outcomes. The average cost per UP in Spain is estimated at €1790.9.

### Table 6. Total Cost of Unintended Pregnancies (contraception failure)

| Contraceptive method | Failure %* | Number of failures in 5 years | Cost of UP in 5 years (€ MM) | Cost per woman of UP in 5 years (€) |
|----------------------|------------|------------------------------|-------------------------------|-----------------------------------|
| COC                  | 9.0%       | 1 063 249                    | 1904.1                        | 805.9                             |
| Gestagen-only OCs    | 9.0%       | 9 800                        | 17.5                          | 805.9                             |
| Vaginal ring         | 9.0%       | 166 592                      | 298.3                         | 805.9                             |
| Patch                | 9.0%       | 24 499                       | 43.9                          | 805.9                             |
| Implant              | 0.1%       | 218                          | 0.4                           | 4.5                               |
| Injection            | 6.0%       | 6533                         | 11.7                          | 537.3                             |
| LNG-IUS12            | 0.2%       | 280                          | 0.5                           | 17.9                              |
| LNG-IUS20            | 0.2%       | 3517                         | 6.3                           | 17.9                              |
| Copper IUD           | 0.8%       | 14 863                       | 26.6                          | 71.6                              |
| Male condom          | 18.0%      | 2 783 066                    | 4984.1                        | 1611.8                            |
| Total                |            | 4 072 616                    | 7293.5                        | 1078.6                            |

\(^{\text{MM: € million. UP: unintended pregnancies}}\)

\(^{\text{* Obtained from }^1\text{ and }^{12}}\)

Contraception Cost per Woman and Method

Finally, the average cost per woman and method, considering total 5-year costs of gynecologist consultations and diagnostic tests, acquisition cost and the cost of UP derived from therapy failure was estimated and compared.

### Results

In Spain, 87.3% of women use reversible contraceptive methods based on the SEC survey,\(^3\) resulting in approximately 6.8 million users (Table 1). The usage of LNG-IUS12 was estimated based on the opinions of experts, who considered that 5% of LNG-IUS20 users and 2.5% of copper IUD users switched to LNG-IUS12. As a result, LNG-IUS12 is used by 0.4% of women, LNG-IUS20 by 5.2% and copper IUD by 5.5%. The most commonly used reversible methods are male condom (45.7%) and COC (34.9%).
The preferred contraceptive methods according to women's age are COC, male condom and vaginal ring for women between 15 and 29 years of age, according to data provided by experts based on their experience. In women between 30 and 34 years of age, preferences are for COC, male condom and LNG-IUS20, while from 35 to 49 years, LNG-IUS20 is the preferred contraceptive method, followed by male condom and copper IUD. Women over 35 years of age prefer long-term contraception methods, such as LNG-IUS and copper IUD, due to safety and user non-dependence compliance. Moreover, when contraception is considered at mid-term based on input obtained from the experts, women's preferences tend towards greater use of long-term methods: LNG-IUS20 and copper IUD are each used by 11.0% of women and the vaginal ring by 10.0%, while male condom and COC are used by only 23.0% and 29.0% of women, respectively.

On average, the percentage change in contraception method is 68.0% for injection, 60.0% for male condom, 53.0% for gestagen-only OCs, 40.0% for patch, 37.0% for COC, 33.0% for vaginal ring, 32.0% for implant, 25.0% for copper IUD, 10.0% for LNG-IUS20 and 9.0% for LNG-IUS12. This data was provided by experts. The main reason for method withdrawal is the onset of adverse events (AE), followed by discomfort and lack of compliance. Considering each reversible method, the main reasons for withdrawal from COC is lack of compliance, followed by AE and discomfort. Women using gestagen-only OCs change mainly because of AE, lack of compliance and discomfort, while the patch is normally replaced by another method due to AE, discomfort and misuse. Vaginal ring, LNG-IUS and copper IUD users typically decide to change their contraceptive method mainly due to AE, other reasons (amenorrhea, overweight) and discomfort. Male condom withdrawal responds to the lack of compliance, misuse and discomfort, while implant and injection is mostly withdrawn because of AE.

Cost of Contraceptive Therapy Initiation

Table 1 shows the total costs of the first consultation with the gynecologist to initiate contraceptive therapy. Total costs of diagnostic tests required to initiate contraceptive therapy with each method are shown in Table 2. The highest costs come from the COC method, since it is the one that requires the most diagnostic tests, followed by copper IUD, LNG-IUS20, and vaginal ring.

Cost of Follow-up Consultations

The methods requiring the highest number of follow-up visits are implant and copper IUD to monitor bleeding adverse events. However, the highest cost is accounted for by COC and male condom, the most frequently used methods in Spain (Table 3).

Total Cost of Medical Management

The total 5-year cost of medical care (initial and follow-up consultations) and the cost of the diagnostic tests amounts to €2.1 billion (Table 4). The main cost drivers are COC (€850.3 million) and male condom (€629.3 million).

Contraceptive Method Acquisition Costs

The acquisition cost for each contraceptive option during a period of 5 years is shown in Table 5. LARC methods (LNG-IUS20, LNG-IUS12, copper IUD, implant and injection) are associated with the lowest cost, while the highest cost corresponds to SARC methods, mainly COC, male condom, and vaginal ring.
Cost of Unintended Pregnancies

The annual direct cost of UP in a period of 5 years is €7.3 billion. Condoms and COC account for €5 billion (68.3%) and €1.9 billion (26.1%), respectively, while all LARC (LNG-IUS20, LNG-IUS12, copper IUD, implant and injectable) only amount to €45.5 million (0.6%). The lowest costs of UP due to method failure come from implant, LNG-IUS12 and LNG-IUS20, representing only 0.1% of the total UP cost (€4.5, €17.9 and €17.9 per woman over 5 years, respectively). The average cost per woman of UP in 5 years is estimated at €1078.6 (Table 6).

Total Costs of Reversible Contraception

The total 5-year costs of the management of reversible contraception in Spain amount to €12.5 billion, mainly coming from male condom (51.0%) and COC methods (35.8%) due to higher frequency of use and a higher number of UP. These two methods are associated with a high rate of failure (18.0% and 9.0%, respectively) (1,12). The other methods, representing 13.2% of total costs, are: vaginal ring (7.2%), patch (1.0%), copper IUD (2.0%), LNG-IUS20 (1.8%), implant (0.7%), gestagen-only OCs (0.3%), LNG-IUS12 (0.2%) and injection (0.2%) (Table 7).

In the analysis of 5-year costs per woman and method, the methods with the highest costs are vaginal ring (€2427.8) and patch (€2402.6), while the least costly options are LNG-IUS20 (€630.4), copper IUD (€658.2) and LNG-IUS12 (€703.8) (Figure 1).

Figure 1. Average Cost per Woman and Contraceptive Method in a Period of 5 Years
### Table 7. Total Cost Associated to Reversible Contraception in a Period of 5 Years

| Contraceptive method | Cost related to 5-year consultations | Total cost of diagnostic tests | 5-year acquisition cost | Cost of UP in 5 years | TOTAL COST in 5 years |
|----------------------|--------------------------------------|--------------------------------|-------------------------|-----------------------|-----------------------|
|                      | € MM | % | € MM | % | € MM | % | € MM | % | € MM | % | € MM | % |
| COC                  | 790.2 | 17.6% | 60.1 | 1.3% | 1723.2 | 38.5% | 1904.1 | 42.5% | 4477.6 | 35.8% |
| Gestagen-only OCs    | 9.3 | 28.8% | 0.6 | 1.7% | 4.8 | 15.0% | 17.5 | 54.5% | 32.2 | 0.3% |
| Vaginal ring         | 111.7 | 12.4% | 9.4 | 1.0% | 479.3 | 53.3% | 298.3 | 33.2% | 898.8 | 7.2% |
| Patch                | 17.3 | 13.2% | 1.4 | 1.1% | 68.3 | 52.2% | 43.9 | 33.5% | 130.8 | 1.0% |
| Implant              | 55.4 | 67.6% | 2.2 | 2.7% | 24.0 | 29.2% | 0.4 | 0.5% | 81.9 | 0.7% |
| Injection            | 6.5 | 32.9% | 0.6 | 3.2% | 0.9 | 4.7% | 11.7 | 59.2% | 19.8 | 0.2% |
| LNG-IUS12            | 9.8 | 49.8% | 0.8 | 4.1% | 8.6 | 43.6% | 0.5 | 2.5% | 19.7 | 0.2% |
| LNG-IUS20            | 171.5 | 77.4% | 10.2 | 4.6% | 33.7 | 15.2% | 6.3 | 2.8% | 221.7 | 1.8% |
| Copper IUD           | 194.8 | 79.7% | 10.8 | 4.4% | 12.4 | 5.1% | 26.6 | 10.9% | 244.6 | 2.0% |
| Male condom          | 629.3 | 9.9% | 0.0 | 0.0% | 757.1 | 11.9% | 4984.1 | 78.2% | 6370.5 | 51.0% |
| Total                | 1995.7 | 16.0% | 96.0 | 0.8% | 3112.3 | 24.9% | 7293.5 | 58.4% | 12497.6 | 100% |

€ MM: € million
% Total cost: contribution of the cost of each method to the overall 5-year cost.

### Discussion

The contraceptive use patterns among Spanish women are influenced by factors such as age, number of children, socio-economic status, and information received during contraceptive counselling.15 Despite the wide availability of contraceptive methods in Spain, UP are still numerous, resulting in elevated costs for the SNHS.1 However, the economic burden of contraception management in Spain had not been previously assessed. This study is the first to estimate the total cost of reversible contraception management in Spain over a period of 5 years from the perspective of the user and the SNHS, considering the main healthcare resources used, ie, first visit and diagnostic tests to initiate contraceptive therapy and follow-up consultations, contraceptive method acquisition cost, and related UP costs. The results show that total 5-year direct costs of reversible contraception management in Spain amount to €12.5 billion. More than half of the cost is attributable to UP, mainly explained by inconsistent or incorrect use of the contraceptive method and a lack of user compliance.16

Short-term methods, SARC, are chosen by 87.3% of women using reversible contraception.3 Male condom and COC are the methods preferred by young women, based on previous studies published in Spain.3,17 However, these two methods have the highest failure rates, 18.0% and 9.0% for condom and COC, respectively.1,12 Women in the middle age range prefer both short- and long-term methods: oral contraception, condom, copper IUD, and LNG-IUS20. The overall LARC use estimated in this study according to Spanish data3 is relatively low (12.7% of women using reversible methods), which is consistent with previous estimations about the low use of LARC among adolescents (2.5%) and young adult women (5.4%) in the United States18 and by 10.0% of women of childbearing age in Europe, with a mean age of LARC users above 30 years for 57–91% of cases.19 The present study shows that long-term methods, such as LNG-IUS20 and copper IUD, are selected by women over 35 years of age who seek safety and user-independent compliance. These methods with lack of dependence on the user’s compliance could reduce the number of UP among young women worldwide, as well as the high economic burden incurred by national health systems, as recognized by world health organizations.20,21 Implant and LNG-IUS are associated with the lowest failure rates (0.1% and 0.2%, respectively),1,12 compared
with the high rates of SARC methods (18.0% for condom and 9.0% for oral contraceptives, vaginal ring and patch). Vaginal ring and patch result in the highest cost per woman in a period of 5 years for the SNHS, while condom and COC also result in higher costs than LNG-IUS and copper IUD. These findings are in line with other published international studies, demonstrating that LNG-IUS, intrauterine devices and implants are the most effective contraceptive methods.

Poor compliance with SARC options may explain the paradoxical association between an increase in elective abortions and an increase in the use of contraception in Spain. The high rates of UP in Spain might be related to the high use of SARC which, to be effective, need to be associated with user compliance. National surveys show a substantial rate of non-compliance affecting oral contraception, and inconsistent use of condoms (20.0% of users), particularly by young people. These two contraceptive methods are the most commonly used in Spain. Absence of contraception, contraception withdrawal and poor user-compliance are well-known causes of UP resulting in voluntary abortions. For example, in a recent study in Spanish women who voluntarily interrupted pregnancy, non-compliant behavior was reported by 77.0% of those using condoms and by 84.0% of those using COC. Among women employing the vaginal ring, 25.0% reported delay in insertion and among users of the skin patch, 58.0% mentioned delayed application of the patch.

These data reflect the incorrect and inconsistent use of contraception in Spain, resulting in a major public health issue with significant economic and social implications. Based on the data included in the economic analysis, this study demonstrates that LNG-IUS methods and intrauterine devices are the most economic contraceptive methods in Spain in the long term, both for women and the SNHS.

This study has limitations inherent to the analysis. The study was conducted from the perspective of the SNHS and these results cannot be extrapolated to other countries. Public prices of contraceptive methods were calculated according to the catalogues of 3 out of 17 Spanish Autonomous Communities (Andalusia, Catalonia and Madrid). However, these regions are the most populated, representing 48% of the Spanish population. As no Spanish data were available for contraceptive failure rates for ‘typical use’, estimates were obtained from US data. Additionally, the economic analysis only reflects the most representative healthcare costs associated with the current contraception care pathway in Spain. Adverse events costs related with each contraceptive option (ie, bleeding irregularities, uterine perforation, pelvic infection or ovarian cysts) are not included in the analysis. Further analyses including additional costs, such as adverse events treatment or different contraception therapy failure rates, could yield different results. Despite the study limitations, this analysis could estimate the potentially avoidable costs for the Spanish NHS and provide some guidance as to the benefits of contraception policy implementation.

**Conclusions**

Patterns of the use of contraceptives in Spain are characterized by a high use of SARC methods, especially in young women. Spanish women over 35 years of age are more worried about effectiveness and user-independent compliance, preferring LARC, especially LNG-IUS and copper IUD, as their contraceptive methods of choice. Moreover, these methods show lower 5-year costs related to contraception management and lower withdrawal rates, compared to SARC, resulting in the most economic contraceptive options for women and for the Spanish public health system. Increased use of LARC could contribute to more effective contraception with a significant reduction in UP and potential cost-savings for the SNHS.
Abbreviations

AE: Adverse Events; COC: Combined Oral Contraceptives; IUD: Intrauterine Device; LARC: Long-Acting Reversible Contraceptives; LNG-IUS: Levonorgestrel-releasing intrauterine system; LNG-IUS12: Levonorgestrel-releasing intrauterine system Jaydess 12μg/day; LNG-IUS20: Levonorgestrel-releasing intrauterine system Mirena 20μg/day; MHSSE: Ministry of Health, Social Services and Equality; OCs: Oral Contraceptives; SARC: Short-Acting Reversible Contraceptives; SEC: Spanish Society of Contraception; SNHS: Spanish National Health System; UP: Unintended Pregnancies.

References

1 Lete I, Hassan F, Chatzitheofilou I, et al. Direct costs of unintended pregnancy in Spain. *Eur J Contracept Reprod Heal Care*. 2015;20(4):308–18.

2 Dueñas JL, Lete I, Bermejo R, et al. Trends in the use of contraceptive methods and voluntary interruption of pregnancy in the Spanish population during 1997-2007. *Contraception*. 2011;83(1):82–7.

3 Spanish Society of Contraception. Contraception survey 2016. Available from: http://sec.es. Accessed April 2017.

4 National Statistics Institute (INE). Available from: http://www.ine.es/jaxi/Tabla.htm?path=/t20/p278/p01/2016-2066/10/&file=01001.px&L=0. Accessed April 2017.

5 Serrano I, Doval J, Lete I, et al. Contraceptive practices of women requesting induced abortion in Spain: A cross-sectional multicentre study. *Eur J Contracept Reprod Heal Care*. 2012;17(3):205–11.

6 BOJA, “Official Bulletin of the Andalusian Autonomous Government”. Order of October 14, 2005. http://www.juntadeandalucia.es/boja/2005/210/d28.pdf. 2005;46–83.

7 Official Gazette of the Autonomous Government of Catalonia. Order SLT/30/2013, February 20, 2013. 2013;10695–862.

8 Official Gazette of Madrid. Order 731/2013, September 6, 2013. 2013;8–30.

9 National Statistics Institute (INE). Update of income with the general CPI (IPC base system 2016) for complete annual periods. http://www.ine.es/calcula/index.do?L=0. Accessed April 2017.

10 BotPlus Web 2.0., General Council of Spanish Pharmacists. Available from: https://botplusweb.portalfarma.com/. Accessed February 2016.

11 Official State Gazette (BOE). 24 May 2010. Article 8. p. 48-50. Available at: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2010-8228.

12 Trussell J. Contraceptive failure in the United States. *Contraception*. 2011;83(5):397–404.

13 Annual number of induced abortions: Voluntary Termination of Pregnancy, 2014. Spanish Ministry of Health, Social Services and Equality. Available from: http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/embrazo/tablas_figuras.htm. Accessed April 28.

14 Ministry of Health, Social Services and Equality. Certificates of Discharge of the National Health System Register. CMBD. State Regulation. Available from: http://www.msc.es/en/estadEstudios/estadisticas/cmbd.htm.

15 Lete I, Pérez-Campos E. Differences in contraceptive use between Spanish female healthcare providers and Spanish women in the general population aged 23 to 49 years: the HABITS Study. *Eur J Contracept Reprod Heal Care*. 2014;19(3):161–8.
16 Parks C, Peipert J. Eliminating Health Disparities in Unintended Pregnancy with Long-Acting Reversible Contraception (LARC). *Am J Obstet Gynecol*. 2016;214(6):681–8.

17 Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15-44: United States, 2011-2013. *NCHS Data Brief*. 2014;(173):1–8.

18 Whitaker AK, Sisco KM, Tomlinson AN, Dude AM, Martins SL. Use of the intrauterine device among adolescent and young adult women in the United States from 2002 to 2010. *J Adolesc Heal*. 2013;53(3):401–6.

19 Haimovich S. Profile of long-acting reversible contraception users in Europe. *Eur J Contracept Reprod Heal Care*. 2009;14(3):187–95.

20 WHO. World Health Organization. From Evidence to Policy: Expanding Access to Family Planning Strategies to increase use of long-acting and permanent contraception. Available from: http://apps.who.int/iris/bitstream/10665/75161/1/WHO_RHR_HRP_12.20_eng.pdf?ua=1. 2012.

21 ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Long-Acting Reversible Contraception. *Work Group Obs Gynecol*. 2009;114(6):1434–8.

22 Parrilla JJ, Coll C, Bajo JM, Balasch J, Calaf J, Cano A et al. Analysis of compliance with oral contraception in Spain. *Eur J Contracept Reprod Heal Care*. 1996;1(4):337–47.

23 Seventh Contraception Survey in Spain, 2011. Bayer HealthCare. Available at: http://www.acaive.com/pdf/Encuesta-anticonecepcion-Equipo-Daphne-26-10-11-2.pdf. Accessed April 2016.

24 Creanga AA, Acharya R, Ahmed S, Tsui AO. Contraceptive discontinuation and failure and subsequent abortion in Romania: 1994-99. *Stud Fam Plann*. 2007;38(1):23–34.

25 Palanivelu LM, Oswal A. Contraceptive practices in women with repeat termination of pregnancies. *J Obst Gynaecol*. 2007;27(8):832–4.

26 Ingham R, Lee E, Clements SJ, Stone N. Reasons for second trimester abortion in England and Wales. *Reprod Heal Matters*. 2008;16(31 Suppl):18–29.